carnitine has been researched along with Anorexia Nervosa in 8 studies
Anorexia Nervosa: An eating disorder that is characterized by the lack or loss of APPETITE, known as ANOREXIA. Other features include excess fear of becoming OVERWEIGHT; BODY IMAGE disturbance; significant WEIGHT LOSS; refusal to maintain minimal normal weight; and AMENORRHEA. This disorder occurs most frequently in adolescent females. (APA, Thesaurus of Psychological Index Terms, 1994)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors relate the results of studying intellectual work fitness in patients with anorexia nervosa (in the stage of cachexia) receiving the vitamin-like drugs carnitine and cobamamide." | 9.07 | [Effects of carnitine and cobamamide on the dynamics of mental work capacity in patients with anorexia nervosa]. ( Kareva, MA; Korchak, GM; Korkina, MV, 1992) |
| "To assess the role of carnitine in the skeletal myopathy present in anorexia nervosa." | 7.70 | Carnitine levels in patients with skeletal myopathy due to anorexia nervosa before and after refeeding. ( McLoughlin, DM; Morton, J; Russell, GF; Whiting, S, 1999) |
| "We reported an 18-year-old woman with anorexia nervosa and liver damage who showed carnitine deficiency." | 7.69 | [A case of secondary carnitine deficiency due to anorexia nervosa and severe liver damage]. ( Fukusako, T; Kato, M; Morimatsu, M; Negoro, K; Tsuda, N, 1995) |
| "The effects of carnitine and cobamamide were studied at the unspecific stage of anorexia nervosa treatment." | 7.67 | [Clinico-experimental substantiation of the use of carnitine and cobalamin in the treatment of anorexia nervosa]. ( Korchak, GM; Korkina, MB; Medvedev, DI, 1989) |
| "The authors relate the results of studying intellectual work fitness in patients with anorexia nervosa (in the stage of cachexia) receiving the vitamin-like drugs carnitine and cobamamide." | 5.07 | [Effects of carnitine and cobamamide on the dynamics of mental work capacity in patients with anorexia nervosa]. ( Kareva, MA; Korchak, GM; Korkina, MV, 1992) |
| "To assess the role of carnitine in the skeletal myopathy present in anorexia nervosa." | 3.70 | Carnitine levels in patients with skeletal myopathy due to anorexia nervosa before and after refeeding. ( McLoughlin, DM; Morton, J; Russell, GF; Whiting, S, 1999) |
| "We reported an 18-year-old woman with anorexia nervosa and liver damage who showed carnitine deficiency." | 3.69 | [A case of secondary carnitine deficiency due to anorexia nervosa and severe liver damage]. ( Fukusako, T; Kato, M; Morimatsu, M; Negoro, K; Tsuda, N, 1995) |
| "The effects of carnitine and cobamamide were studied at the unspecific stage of anorexia nervosa treatment." | 3.67 | [Clinico-experimental substantiation of the use of carnitine and cobalamin in the treatment of anorexia nervosa]. ( Korchak, GM; Korkina, MB; Medvedev, DI, 1989) |
| "Refeeding syndrome has been observed in patients receiving nutrition after a prolonged period of malnourishment and is characterized by multiple metabolic derangements." | 1.38 | Fatty emaciation: a case report of suspected fat overload syndrome in oral refeeding. ( Macher, AD; Maviglia, SM; Palazuelos, D, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Macher, AD | 1 |
| Palazuelos, D | 1 |
| Maviglia, SM | 1 |
| LEMARCHANT, JM | 1 |
| TEITELBAUM, M | 1 |
| MILLER, G | 1 |
| Fukusako, T | 1 |
| Negoro, K | 1 |
| Tsuda, N | 1 |
| Kato, M | 1 |
| Morimatsu, M | 1 |
| Moyano, D | 1 |
| Vilaseca, MA | 1 |
| Artuch, R | 1 |
| Lambruschini, N | 1 |
| Morton, J | 1 |
| McLoughlin, DM | 1 |
| Whiting, S | 1 |
| Russell, GF | 1 |
| Korkina, MV | 1 |
| Korchak, GM | 2 |
| Kareva, MA | 1 |
| Korkina, MB | 1 |
| Medvedev, DI | 1 |
| Böhmer, T | 1 |
| Rydning, A | 1 |
| Solberg, HE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy[NCT00374075] | Phase 1 | 42 participants | Interventional | 2003-09-30 | Completed | ||
| Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)[NCT00661453] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)[NCT00227266] | Phase 2 | 94 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00661453)
Timeframe: -2 weeks, time 0, 3 months, 6 months
| Intervention | g (Mean) | |||||
|---|---|---|---|---|---|---|
| Lean Mass Baseline | Lean Mass 3 months | Lean Mass 6 months | Fat Mass Baseline | Fat Mass 3 months | Fat Mass 6 months | |
| SMA Type 1 | 4317.15 | 4993.92 | 5133.83 | 3011.37 | 3618.25 | 4316.08 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 2.28 | 2.32 |
| Cohort 1b Sitters Treatment | 2.93 | 2.37 |
| Cohort 2 Standers and Walkers - Treatment | 5.52 | 6.56 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 1.91 | 1.44 |
| Cohort 1b Sitters Treatment | 2.2 | 1.8 |
| Cohort 2 Standers and Walkers - Treatment | 5.3 | 5.85 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 5.46 | 5.28 |
| Cohort 1b Sitters Treatment | 5.45 | 5.26 |
| Cohort 2 Standers and Walkers - Treatment | 14.85 | 16.26 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 3.6 | 3.74 |
| Cohort 1b Sitters Treatment | 4.6 | 3.4 |
| Cohort 2 Standers and Walkers - Treatment | 13.65 | 16.85 |
Comparison of Modified Hammersmith Change from baseline to 6 months. Scores range from 0 to 40. A higher score indicates a better outcome. This scale is used to assess gross motor abilities of non-ambulant children with SMA in multiple research trials as well as in clinical settings. (NCT00227266)
Timeframe: 0 months, 6 months
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Baseline visit (0 weeks) | 6 Month visit (V2) | Change from Baseline | |
| Cohort 1a Sitters Placebo Then Treatment | 20.0 | 20.6 | 0.6 |
| Cohort 1b Sitters Treatment | 16.6 | 16.8 | 0.2 |
"Baseline Modified Hammersmith Extend testing. The baseline test is the score they receive during their screening visits. This scale ranges from 0 to 56. A higher score indicates a better outcome.~This scale is used to assess gross motor abilities of children with SMA in multiple research trials as well as in clinical settings." (NCT00227266)
Timeframe: 1 month prior to enrollment, at enrollment (0 months)
| Intervention | Score (Mean) | |
|---|---|---|
| Modified Hammersmith Extend at S1 (-4 weeks) | Modified Hammersmith Extend at S2 (0 weeks) | |
| Cohort 2 Experimental | 47.0 | 48.3 |
1 trial available for carnitine and Anorexia Nervosa
| Article | Year |
|---|---|
[Effects of carnitine and cobamamide on the dynamics of mental work capacity in patients with anorexia nervosa].
Topics: Anorexia Nervosa; Cachexia; Carnitine; Cobamides; Humans; Intelligence; Mental Fatigue; Placebos; Wo | 1992 |
7 other studies available for carnitine and Anorexia Nervosa
| Article | Year |
|---|---|
Fatty emaciation: a case report of suspected fat overload syndrome in oral refeeding.
Topics: Administration, Oral; Anorexia Nervosa; Carnitine; Dietary Fats; Female; Humans; Hyperlipidemias; Ma | 2012 |
[CARNITINE IN THE TREATMENT OF 40 PATIENTS HOSPITALIZED FOR NERVOUS THINNESS].
Topics: Adolescent; Anorexia Nervosa; Anxiety; Carnitine; Folic Acid; Geriatrics; Humans; Thinness; Vitamin | 1964 |
[A case of secondary carnitine deficiency due to anorexia nervosa and severe liver damage].
Topics: Adolescent; Anorexia Nervosa; Carnitine; Female; Humans; Liver Diseases | 1995 |
Plasma amino acids in anorexia nervosa.
Topics: Adolescent; Amino Acids; Anorexia Nervosa; Carnitine; Chromatography, Ion Exchange; Cysteine; Female | 1998 |
Carnitine levels in patients with skeletal myopathy due to anorexia nervosa before and after refeeding.
Topics: Adult; Anorexia Nervosa; Body Mass Index; Carnitine; Female; Humans; Mitochondrial Myopathies; Muscl | 1999 |
[Clinico-experimental substantiation of the use of carnitine and cobalamin in the treatment of anorexia nervosa].
Topics: Animals; Anorexia Nervosa; Body Weight; Carnitine; Cerebral Cortex; Disease Models, Animal; Drug Eva | 1989 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |